Abstract
The TMPRSS2-ERG fusion, present in approximately 50% of prostate cancers, is less common in prostatic intraepithelial neoplasia (PIN), raising questions about whether TMPRSS2-ERG contributes to disease initiation. We identified the translational start site of a common TMPRSS2-ERG fusion and showed that transgenic TMPRSS2-ERG mice develop PIN, but only in the context of PI3-kinase pathway activation. TMPRSS2-ERG–positive human tumors are also enriched for PTEN loss, suggesting cooperation in prostate tumorigenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kumar-Sinha, C., Tomlins, S.A. & Chinnaiyan, A.M. Nat. Rev. Cancer 8, 497–511 (2008).
Perner, S. et al. Am. J. Surg. Pathol. 31, 882–888 (2007).
Tomlins, S.A. et al. Science 310, 644–648 (2005).
Jhavar, S. et al. J. Mol. Diagn. 10, 50–57 (2008).
Ellwood-Yen, K. et al. Cancer Cell 4, 223–238 (2003).
Zhang, J., Thomas, T.Z., Kasper, S. & Matusik, R.J. Endocrinology 141, 4698–4710 (2000).
Majumder, P.K. et al. Proc. Natl. Acad. Sci. USA 100, 7841–7846 (2003).
Carver, B.S. et al. Nat. Genet. advance online publication, doi:10.1038/ng.370 (26 April 2009).
Di Cristofano, A., Pesce, B., Cordon-Cardo, C. & Pandolfi, P.P. Nat. Genet. 19, 348–355 (1998).
Attard, G. et al. Oncogene 27, 253–263 (2008).
Yoshimoto, M. et al. Mod. Pathol. 21, 1451–1460 (2008).
Sun, C. et al. Oncogene 27, 5348–5353 (2008).
Klezovitch, O. et al. Proc. Natl. Acad. Sci. USA 105, 2105–2110 (2008).
Tomlins, S.A. et al. Neoplasia 10, 177–188 (2008).
Xu, Q. et al. Proc. Natl. Acad. Sci. USA 104, 17771–17776 (2007).
Acknowledgements
J.C.K. is supported by a NIH/NCI Ruth L. Kirschstein NRSA (7F32CA113132). C.L.S. is supported by the Howard Hughes Medical Institute and the Doris Duke Foundation. B.S.T. is supported by a MSKCC Geoffrey Beene Cancer Research Center fellowship. We thank K. Yen, N. Clegg, Y. Chen, T. Shamu and the MSKCC CMG, Proteomics, and Molecular Cytology Core Facilities for technical help and/or discussions. We also thank P.P. Pandolfi (Beth Israel Deaconess Medical Center, Harvard University) for sharing unpublished results and V. Vasioukhin (Fred Hutchinson Cancer Research Center) for providing transgenic prostate lobes.
Author information
Authors and Affiliations
Contributions
J.C.K., J.X., J.W., D.H.L., B.S.C. and C.L.S. designed, created and characterized the transgenic animals. S.S.C. and R.D.C. performed the pathological analysis. J.X. and C.L.S. identified the potential start site. H.H., B.S.T., C.S. and W.L.G. performed and analyzed the CGH and exon array experiments. J.C.K. and C.L.S. wrote the initial draft of the manuscript and all authors contributed to the final version.
Corresponding author
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1 and 2, Supplementary Methods (PDF 961 kb)
Supplementary Table 1
aCGH data (XLS 96 kb)
Supplementary Table 2
Raw expression data (XLS 461 kb)
Supplementary Table 3
Log transformed ERG core expression data (XLS 107 kb)
Supplementary Table 4
Merged expression data (XLS 38 kb)
Supplementary Table 5
Discretized aCGH and expression data (XLS 36 kb)
Rights and permissions
About this article
Cite this article
King, J., Xu, J., Wongvipat, J. et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 41, 524–526 (2009). https://doi.org/10.1038/ng.371
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.371
This article is cited by
-
Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis
Nature Communications (2023)
-
Computational epigenetic landscape analysis reveals association of CACNA1G-AS1, F11-AS1, NNT-AS1, and MSC-AS1 lncRNAs in prostate cancer progression through aberrant methylation
Scientific Reports (2022)
-
TMPRSS2-ERG promotes the initiation of prostate cancer by suppressing oncogene-induced senescence
Cancer Gene Therapy (2022)
-
Extensive germline-somatic interplay contributes to prostate cancer progression through HNF1B co-option of TMPRSS2-ERG
Nature Communications (2022)
-
Transcriptional landscape of PTEN loss in primary prostate cancer
BMC Cancer (2021)